Results 91 to 100 of about 3,819 (202)

Fibrilación auricular en los servicios de urgencias hospitalarias [PDF]

, 2016
La fibrilación auricular (FA) es la arritmia cardíaca sostenida más frecuente en la población. Es una enfermedad grave y es un factor predictivo independiente de mortalidad, asociando un riesgo de ictus 5 veces superior a la población general.
García Palacios, José David
core  

International Collaborative Partnership for the Study of Atrial Fibrillation (INTERAF): Rationale, Design, and Initial Descriptives. [PDF]

, 2016
published_or_final_versio
Abe, M, Akao, M, Anderson, KL, Avezum, A, Glusenkamp, N, Hsu, JC, Kohsaka, S, Lane, DA, Lip, GY, Ma, CS, Maddox, TM, Masoudi, FA, Potpara, TS, Rumsfeld, JS, Siong, TW, Tse, HF, Turakhia, MP   +16 more
core   +2 more sources

Practical considerations on anticoagulation reversal: spotlight on the reversal of dabigatran

Vascular Health and Risk Management, 2019
David Giannandrea,1,2,* Anna Mengoni,3,* Erberto Carluccio,3 Giuseppe Ambrosio31Neurology Departement - Stroke Unit, Gubbio/Gualdo Tadino Hospitals, Perugia, Italy; 2Association “Naso Sano”, Umbria Regional Registry of No-Profit Organization,
Giannandrea D, Mengoni A, Carluccio E, Ambrosio G   +3 more
doaj  

First Reported Case of Hemopericardium Related to Dabigatran Use Reversed by New Antidote Idarucizumab

Case Reports in Cardiology, 2017
Dabigatran, the first novel oral anticoagulant (NOAC) with a reversal agent, heralded a paradigm shift in the treatment of nonvalvular atrial fibrillation.
Steven Song, Joselle Cook, Clive Goulbourne, Matthew Meade, Louis Salciccioli, Jason Lazar   +5 more
doaj   +1 more source

Direct oral anticoagulants: first airbag

Медицинский совет, 2019
The safety profile of oral anticoagulants (DOACs) was confirmed in the large-scale studies, the increased risk of hemorrhagic events does still exist, which may be caused by the nature of the patient’s concomitant pathology, the resulting injury or the ...
A. N. Sokolova, A. I. Skripka
doaj   +1 more source

Jefferson Digital Commons quarterly report: July-September 2018 [PDF]

, 2018
This quarterly report includes: New Collection Alert Articles Code Red: Battling the Plague of Gun Violence Dissertations From the Archives Grand Rounds and Lectures House Staff Quality Improvement and Patient Safety Posters Journals and Newsletters ...
Copeland, LIBT, James, Duinkerken, MSI, Kelsey   +1 more
core   +1 more source

Modern strategy of antithrombotic therapy in patients with coronary artery disease and atrial fibrillation after percutaneous coronary intervention

Российский кардиологический журнал, 2019
Reducing of cardiovascular risk, morbidity and mortality is considered as one of the main aims of modern cardiology, which should help increase life expectancy.
Yu. A. Karpov
doaj   +1 more source

Perspectivas clínicas del manejo de la hemorragia en el paciente tratado con anticoagulante oral: estudio DECOVER [PDF]

, 2018
Objetivo. Evaluar el grado de acuerdo entre hematólogos y urgenciólogos respecto a las mejores prácticas para el manejo de hemorragias y la reversión de la anticoagulación oral. Método.
Camats, Míriam, Coll-Vinent i Puig, Blanca, Crespo Palomo, Carlos, González-Porras, José Ramón, Grupo DECOVER, Lecumberri, Ramón, Marco, Pascual, Martín, Alfonso, Mateo, José, Roldán, Vanesa, Soulard, Stéphane, Suero, Coral, Vicente, Vicente   +12 more
core  

Idarucizumab for dabigatran reversal

Thrombosis research, 2023
Background: Idarucizumab has been approved to reverse the anticoagulant effect of dabigatran. However, there is little knowledge of the effectiveness and safety of idarucizumab in daily practice. Aims: This systematic review and meta-analysis aims to evaluate the use, effectiveness and outcomes of idarucizumab.
van der Horst, S. F. B., Martens, E. S. L., den Exter, P. L., Bos, M. H. A., van Mens, T. E., Huisman, M. V., Klok, F. A.   +6 more
openaire   +1 more source

Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers. [PDF]

, 2019
BACKGROUND: Ticagrelor is an oral P2Y12 inhibitor that is used with aspirin to reduce the risk of ischemic events among patients with acute coronary syndromes or previous myocardial infarction.
Arnold, Susan E., Bhatt, Deepak L., Jennings, Lisa K., Lee, John S., Mays, Michael C., Pollack, Charles V., Umstead, Bret R., Weitz, Jeffrey I., Xu, Sherry   +8 more
core   +1 more source